Get the Stockscreener App
54.22
4.19%
-2.37
After Hours:
54.22
Praxis Precision Medicines Inc stock is traded at $54.22, with a volume of 556.91K.
It is down -4.19% in the last 24 hours and up +28.94% over the past month.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
See More
Previous Close:
$56.59
Open:
$56
24h Volume:
556.91K
Relative Volume:
1.58
Market Cap:
$1.10B
Revenue:
$1.77M
Net Income/Loss:
$-123.74M
P/E Ratio:
-5.9128
EPS:
-9.17
Net Cash Flow:
$-95.21M
1W Performance:
-6.53%
1M Performance:
+28.94%
6M Performance:
-29.17%
1Y Performance:
-6.05%
1-Day Range:
$53.71
$56.70
1-Week Range:
$53.71
$61.03
52-Week Range:
$26.70
$91.83
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Name
Praxis Precision Medicines Inc
Sector
Industry
Phone
617-300-8460
Address
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
54.22 | 1.15B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-03-25 | Reiterated | H.C. Wainwright | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Aug-05-24 | Initiated | Oppenheimer | Outperform |
| Jun-24-24 | Initiated | Needham | Buy |
| Jun-18-24 | Initiated | Guggenheim | Buy |
| May-01-24 | Initiated | Robert W. Baird | Outperform |
| Sep-19-23 | Initiated | Truist | Buy |
| Jun-06-22 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Aug-26-21 | Initiated | BofA Securities | Buy |
| Apr-26-21 | Initiated | William Blair | Outperform |
| Nov-11-20 | Initiated | Wedbush | Outperform |
| Nov-10-20 | Initiated | Cowen | Outperform |
| Nov-10-20 | Initiated | Evercore ISI | Outperform |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Praxis Precision Medicines Inc Stock (PRAX) Latest News
Will Praxis Precision Medicines Inc. see short term momentumCommunity Picked Stocks with Trade Insights - Newser
Will Praxis Precision Medicines Inc. stock split in the near futureLow Volatility Stock Analysis With Confidence - Newser
Is Praxis Precision Medicines Inc. stock entering bullish territoryShort-Term Growth Watch with Signal Prediction - Newser
Why Praxis Precision Medicines Inc. stock attracts strong analyst attentionChart-Based Entry Confirmation for Beginners - Newser
What makes Praxis Precision Medicines Inc. stock price move sharplyFree Buy Alerts With Low Risk Confirmation - Newser
Applying sector rotation models to Praxis Precision Medicines Inc.3-Day Market Movement Forecast Analysis - Newser
Detecting price anomalies in Praxis Precision Medicines Inc. with AIMachine Learning Intraday Signal Forecast - Newser
Praxis Precision Medicines to Host Conference Call to Announce Topline Results from the RADIANT Trial and Provide Second Quarter 2025 Financial Results | PRAX Stock News - GuruFocus
Praxis Precision Medicines to Host Conference Call to - GlobeNewswire
Praxis Precision Medicines to Host Conference Call to Announce Topline Results from the RADIANT Trial and Provide Second Quarter 2025 Financial Results - Stock Titan
Buy Signal for Praxis Precision Medicines Inc. Stock Key Technical Indicators to WatchReal-Time Investment Signal Forecast with AI - Newser
What are analysts’ price targets for Praxis Precision Medicines Inc. in the next 12 monthsDaily Trading Tips That Work - jammulinksnews.com
How Praxis Precision Medicines Inc. stock performs during market volatilityFree Stock Selection With High Accuracy - Newser
What is Praxis Precision Medicines Inc. company’s growth strategyBuild a diversified portfolio for stability - jammulinksnews.com
Is Praxis Precision Medicines Inc. stock entering bullish territory Bollinger Band Squeeze and Expansion Analysis - Newser
How volatile is Praxis Precision Medicines Inc. stock compared to the marketUnlock powerful investment tools for free - jammulinksnews.com
Will Praxis Precision Medicines Inc. see short term momentum Buy Signal System Based on Price Action - Newser
Is it too late to sell Praxis Precision Medicines Inc. Free Growth Focused Entry Plan Suggestions - Newser
Is Praxis Precision Medicines Inc. stock overvalued or undervaluedUnlock powerful portfolio optimization tools - jammulinksnews.com
When is Praxis Precision Medicines Inc. stock expected to show significant growthCapitalize on proven trading setups - jammulinksnews.com
Should I hold or sell Praxis Precision Medicines Inc. stock in 2025Unlock powerful portfolio management tools - jammulinksnews.com
Is Praxis Precision Medicines Inc. Stock Overbought or Oversold RSI Indicator Analysis3x Return Stock Radar - Newser
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Stock Holdings Lowered by New York State Common Retirement Fund - Defense World
Does Praxis Precision Medicines Inc. stock pay reliable dividendsProven Trading Plan - Newser
What analysts say about Praxis Precision Medicines Inc. stock outlookFree Market Volatility Navigation Tips - jammulinksnews.com
Will Praxis Precision Medicines Inc. stock benefit from AI tech trendsPhenomenal capital gains - jammulinksnews.com
Praxis Precision Medicines Inc. Stock Analysis and ForecastTremendous return on equity - Autocar Professional
Is Praxis Precision Medicines Inc. a good long term investmentExceptional profit potential - PrintWeekIndia
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
What drives Praxis Precision Medicines Inc. stock priceConsistent triple-digit returns - jammulinksnews.com
What analysts say about Praxis Precision Medicines Inc. stockBreakthrough capital growth - jammulinksnews.com
Major Depressive Disorder Clinical Trials, Companies, - openPR.com
Praxis Precision Medicines Inc Stock (PRAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):